Serial Number
87771739
Owner
Jazz Pharmaceuticals Research UK LimitedAttorney
Michael T. OlsenFiling Date
Jan 26, 2018
CANNABINOID RESEARCH INSTITUTE Trademark
Serial Number: 87771739 • Registration: 5765928
Trademark Classes
Owner Contact Info
Legal Representation
Correspondence Address
Michael T. Olsen Winthrop & Weinstine, P.A.
225 South 6th Street
Suite 3500
Minneapolis, MN 55402
UNITED STATES
Trademark Details
Filing Date
January 26, 2018
Registration Date
May 28, 2019
Cancellation Date
December 12, 2025
Goods & Services
Providing online non-downloadable electronic publications in the nature of newsletters, journals, and books in the field of cannabinoid-based medicines; arranging, conducting and organisation of educational conferences, congresses, seminars and symposiums in the field of cannabinoid-based medicines; information, advisory and consultancy services in relation to all of the aforesaid services
Scientific and technological services and research and design relating thereto, namely, scientific research in the field of cannabinoid-based medicines, research on the subject of pharmaceuticals, and pharmaceutical drug development services, all involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; pharmaceutical research and development services all involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; research, testing and development of pharmaceutical and veterinary preparations all involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; biological, clinical and medical research all involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; conducting clinical trials for others all involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; chemical analysis all involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; information, advisory and consultancy services in relation to all of the aforesaid services
